Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZP9830 in Plaque Psoriasis
NCT07733089Phase 1Recruiting
- Sponsor
- Zealand Pharma
- Start
- Jul 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in plaque psoriasis comparing ZP9830 with Placebo (2 arms). Primary endpoint: Number of Treatment Emergent Adverse Events at Day 85. Started Jul 2026; status: recruiting.
02
Drugs
ZP9830
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07733089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07733089.